Hillstream Biopharma (NASDAQ:CNTN) Announces Earnings Results

Hillstream Biopharma (NASDAQ:CNTN) posted its earnings results on Tuesday. The company reported $0.54 earnings per share (EPS) for the quarter, FiscalAI reports.

Hillstream Biopharma Trading Up 2.1%

CNTN stock opened at $3.15 on Tuesday. The company has a market capitalization of $162.03 million, a P/E ratio of -0.79 and a beta of 1.41. Hillstream Biopharma has a 1-year low of $0.95 and a 1-year high of $9.08.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings started coverage on shares of Hillstream Biopharma in a report on Monday, March 9th. They issued a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Hillstream Biopharma currently has a consensus rating of “Sell”.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.